tiprankstipranks
Maravai Lifesciences Holdings (MRVI)
NASDAQ:MRVI
US Market
MRVI
Maravai Lifesciences Holdings
RESEARCH TOOLSreports
Want to see MRVI full AI Analyst Report?

Maravai Lifesciences Holdings (MRVI) Stock Forecast & Price Target

413 Followers
See the Price Targets and Ratings of:

MRVI Analyst Ratings

Moderate Buy
7Ratings
Moderate Buy
4 Buy
3 Hold
0 Sell
Based on 7 analysts giving stock ratings to
Maravai
Lifesciences Holdings
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MRVI Stock 12 Month Forecast

Average Price Target

$4.82
▲(42.28% Upside)
Based on 7 Wall Street analysts offering 12 month price targets for Maravai Lifesciences Holdings in the last 3 months. The average price target is $4.82 with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 42.28% change from the last price of $3.39.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","4":"$4","7":"$7","2.5":"$2.5","5.5":"$5.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.823333333333333,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.82</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$3.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.5,4,5.5,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.73,3.9046153846153846,4.079230769230769,4.253846153846154,4.428461538461539,4.603076923076923,4.777692307692307,4.952307692307692,5.126923076923077,5.3015384615384615,5.476153846153846,5.650769230769231,5.825384615384616,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.73,3.814102564102564,3.898205128205128,3.982307692307692,4.066410256410256,4.15051282051282,4.234615384615385,4.318717948717949,4.4028205128205125,4.486923076923077,4.571025641025641,4.6551282051282055,4.739230769230769,{"y":4.823333333333333,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.73,3.6738461538461538,3.6176923076923075,3.5615384615384613,3.5053846153846155,3.4492307692307693,3.393076923076923,3.336923076923077,3.2807692307692307,3.224615384615385,3.168461538461538,3.1123076923076924,3.056153846153846,{"y":3,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.13,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.51,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.37,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.25,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.37,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.61,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.87,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.73,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$6.00Average Price Target$4.82Lowest Price Target$3.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on MRVI
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (NASDAQ: HRMY), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Alkermes (NASDAQ: ALKS)
Stifel Nicolaus Analyst forecast on MRVI
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$4→$6
Buy
76.99%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH) and Maravai Lifesciences Holdings (NASDAQ: MRVI)
Deutsche Bank Analyst forecast on MRVI
Justin Bowers
Deutsche Bank
Deutsche Bank
$4.5→$6
Buy
76.99%
Upside
Reiterated
05/08/26
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche BankMaravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
William Blair Analyst forecast on MRVI
Matt Larew
William Blair
William Blair
$3.94
Hold
16.22%
Upside
Reiterated
05/08/26
William Blair Sticks to Its Hold Rating for Maravai Lifesciences Holdings (MRVI)
Craig-Hallum Analyst forecast on MRVI
Matt Hewitt
Craig-Hallum
Craig-Hallum
$5
Buy
47.49%
Upside
Reiterated
05/08/26
Analysts' Top Healthcare Picks: Maravai Lifesciences Holdings (MRVI), Globus Medical (GMED)
Jefferies Analyst forecast on MRVI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$5
Buy
47.49%
Upside
Reiterated
02/26/26
Jefferies Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Robert W. Baird Analyst forecast on MRVI
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$2→$3
Hold
-11.50%
Downside
Reiterated
02/26/26
Maravai Lifesciences price target raised to $3 from $2 at BairdMaravai Lifesciences price target raised to $3 from $2 at Baird
Wells Fargo Analyst forecast on MRVI
Brandon Couillard
Wells Fargo
Wells Fargo
$4→$4.5
Buy
32.74%
Upside
Reiterated
12/15/25
Maravai Lifesciences price target raised to $4.50 from $4 at Wells FargoMaravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo
RBC Capital Analyst forecast on MRVI
Conor McNamara
RBC Capital
RBC Capital
$5
Buy
47.49%
Upside
Reiterated
09/02/25
RBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Morgan Stanley Analyst forecast on MRVI
Tejas Savant
Morgan Stanley
Morgan Stanley
$5
Hold
47.49%
Upside
Reiterated
05/21/25
Hold Rating for Maravai Lifesciences Holdings Amid Revenue Challenges and Uncertainty in CleanCap Orders
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on MRVI
Subbu Nambi
Guggenheim
Guggenheim
―
Hold
―
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (NASDAQ: HRMY), Maravai Lifesciences Holdings (NASDAQ: MRVI) and Alkermes (NASDAQ: ALKS)
Stifel Nicolaus Analyst forecast on MRVI
Daniel Arias
Stifel Nicolaus
Stifel Nicolaus
$4→$6
Buy
76.99%
Upside
Reiterated
05/11/26
Analysts Offer Insights on Healthcare Companies: Astrana Health (NASDAQ: ASTH) and Maravai Lifesciences Holdings (NASDAQ: MRVI)
Deutsche Bank Analyst forecast on MRVI
Justin Bowers
Deutsche Bank
Deutsche Bank
$4.5→$6
Buy
76.99%
Upside
Reiterated
05/08/26
Maravai Lifesciences price target raised to $6 from $4.50 at Deutsche BankMaravai Lifesciences price target raised to $6 from $4.50 at Deutsche Bank
William Blair Analyst forecast on MRVI
Matt Larew
William Blair
William Blair
$3.94
Hold
16.22%
Upside
Reiterated
05/08/26
William Blair Sticks to Its Hold Rating for Maravai Lifesciences Holdings (MRVI)
Craig-Hallum Analyst forecast on MRVI
Matt Hewitt
Craig-Hallum
Craig-Hallum
$5
Buy
47.49%
Upside
Reiterated
05/08/26
Analysts' Top Healthcare Picks: Maravai Lifesciences Holdings (MRVI), Globus Medical (GMED)
Jefferies Analyst forecast on MRVI
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$5
Buy
47.49%
Upside
Reiterated
02/26/26
Jefferies Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Robert W. Baird Analyst forecast on MRVI
Catherine Ramsey Schulte
Robert W. Baird
Robert W. Baird
$2→$3
Hold
-11.50%
Downside
Reiterated
02/26/26
Maravai Lifesciences price target raised to $3 from $2 at BairdMaravai Lifesciences price target raised to $3 from $2 at Baird
Wells Fargo Analyst forecast on MRVI
Brandon Couillard
Wells Fargo
Wells Fargo
$4→$4.5
Buy
32.74%
Upside
Reiterated
12/15/25
Maravai Lifesciences price target raised to $4.50 from $4 at Wells FargoMaravai Lifesciences price target raised to $4.50 from $4 at Wells Fargo
RBC Capital Analyst forecast on MRVI
Conor McNamara
RBC Capital
RBC Capital
$5
Buy
47.49%
Upside
Reiterated
09/02/25
RBC Capital Remains a Buy on Maravai Lifesciences Holdings (MRVI)
Morgan Stanley Analyst forecast on MRVI
Tejas Savant
Morgan Stanley
Morgan Stanley
$5
Hold
47.49%
Upside
Reiterated
05/21/25
Hold Rating for Maravai Lifesciences Holdings Amid Revenue Challenges and Uncertainty in CleanCap Orders
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Maravai Lifesciences Holdings

3 Months
Daniel AriasStifel Nicolaus
Success Rate
9/19 ratings generated profit
47%
Average Return
-3.50%
Copying Daniel Arias's trades and holding each position for 3 Months would result in 47.37% of your transactions generating a profit, with an average return of -3.50% per trade.
1 Year
Matt HewittCraig-Hallum
Success Rate
10/18 ratings generated profit
56%
Average Return
+6.69%
Copying Matt Hewitt's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +6.69% per trade.
2 Years
Matt HewittCraig-Hallum
Success Rate
10/18 ratings generated profit
56%
Average Return
+12.53%
Copying Matt Hewitt's trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +12.53% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MRVI Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
0
0
0
0
0
Buy
9
10
8
7
5
Hold
1
3
3
3
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
10
13
11
10
7
In the current month, MRVI has received 5 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. MRVI average Analyst price target in the past 3 months is 4.82.
Each month's total comprises the sum of three months' worth of ratings.

MRVI Financial Forecast

MRVI Earnings Forecast

Next quarter’s earnings estimate for MRVI is -$0.05 with a range of -$0.07 to -$0.03. The previous quarter’s EPS was $0.01. MRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
Next quarter’s earnings estimate for MRVI is -$0.05 with a range of -$0.07 to -$0.03. The previous quarter’s EPS was $0.01. MRVI beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.

MRVI Sales Forecast

Next quarter’s sales forecast for MRVI is $48.65M with a range of $47.90M to $50.00M. The previous quarter’s sales results were $65.84M. MRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.
Next quarter’s sales forecast for MRVI is $48.65M with a range of $47.90M to $50.00M. The previous quarter’s sales results were $65.84M. MRVI beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MRVI has Performed in-line its overall industry.

MRVI Stock Forecast FAQ

What is MRVI’s average 12-month price target, according to analysts?
Based on analyst ratings, Maravai Lifesciences Holdings’s 12-month average price target is 4.82.
    What is MRVI’s upside potential, based on the analysts’ average price target?
    Maravai Lifesciences Holdings has 42.28% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is MRVI a Buy, Sell or Hold?
          Maravai Lifesciences Holdings has a consensus rating of Moderate Buy which is based on 4 buy ratings, 3 hold ratings and 0 sell ratings.
            What is Maravai Lifesciences Holdings’s price target?
            The average price target for Maravai Lifesciences Holdings is 4.82. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $6.00 ,the lowest forecast is $3.00. The average price target represents 42.28% Increase from the current price of $3.39.
              What do analysts say about Maravai Lifesciences Holdings?
              Maravai Lifesciences Holdings’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
                How can I buy shares of MRVI?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.